IgA Nephropathy research hub

A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients

This study is looking into a new medication called LNP023 for a kidney condition called IgA nephropathy. It compares LNP023 with a dummy pill (placebo) to see if it helps reduce protein in the urine and protect kidney function over time.

Study of BHV-1400 in IgA Nephropathy

This study is testing a new medicine, BHV-1400, for IgA Nephropathy (IgAN). We want to find out if it's safe and if people can take it without too many problems. It's for adults aged 18-65 who have been diagnosed with IgAN.

A Study of Zigakibart in Adults With IgA Nephropathy

This study is testing a new medicine, BION-1301, for adults with IgA Nephropathy to see if it can help their kidneys. It compares the new medicine to a dummy medicine (placebo).

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

This study is testing a new medicine, BION-1301, for people with a kidney disease called IgA Nephropathy (IgAN). The main aims are to check if the medicine is safe and how well it is tolerated in both healthy volunteers and IgAN patients.

Atrasentan in Patients With IgA Nephropathy

This study is testing a new medicine, atrasentan, for people with a kidney disease called IgA nephropathy. It compares atrasentan to a dummy pill (placebo) to see if it can slow down kidney damage and improve kidney function.

National Registry of Rare Kidney Diseases

This registry is collecting information from people with rare kidney diseases across the UK. It aims to improve understanding, create better care guidelines, and help develop new treatments for these conditions. If you have a rare kidney disease, your information could help.

A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy

This study is looking at a new medicine called zigakibart for adults with a kidney condition called IgA nephropathy. It will check if the medicine is safe and how well people tolerate it over a long time, as well as its effects on kidney health.

Atrasentan in Patients With Proteinuric Glomerular Diseases

This study looks at a new medicine called atrasentan for people with certain kidney diseases. It aims to see if atrasentan can help reduce protein in the urine and protect kidney function. Different groups of patients with kidney conditions like IgA nephropathy and diabetic kidney disease are being included.

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy